In Vivo and In Vitro Evaluation of the Heparin Management Test versus the Activated Coagulation Time for Monitoring Anticoagulation Level in Aprotinin-Treated Patients during Cardiac Surgery
DOI:
https://doi.org/10.1532/HSF98.20041134Abstract
Introduction: Monitoring whole blood anticoagulation therapy with the activated coagulation time (kaolin ACT) and the heparin management test (HMT) were correlated in vivo with the plasma anti-activated factor X (anti-Xa) heparin concentration in patients who received variable doses of aprotinin and in vitro in the presence of increasing concentrations of aprotinin.
Methods: In 38 elective cardiac surgical patients who received an average heparin dose of 400 IU/kg and an average total aprotinin dose of 3.6 ´ 106 kallikrein-inhibiting units (KIU), ACT and HMT were measured in duplicate 6 times intraoperatively at predetermined intervals. Blood samples at each interval were also assayed for the anti-Xa plasma heparin concentration with the IL Test heparin chromogenic assay. The influence of increasing concentrations of aprotinin on HMT and ACT was also measured in vitro by using blood samples containing 6 IU/mL heparin from 6 additional patients after adding specific aliquots of aprotinin to achieve concentrations of 50, 100, 200, and 300 KIU/mL aprotinin. Linear regression analysis was used to compare HMT and ACT against anti-Xa. A P level <.05 was required for statistical significance.
Results: Duplicate measurements were taken at all intervals, and HMT and ACT values were significantly correlated, both with each other (r = 0.86; P < .01) and with anti-Xa activity (HMT, r = 0.81 [P < .01]; ACT, r = 0.71 [P < .01]). Aprotinin prolonged both the kaolin ACT and the HMT time in a dose-dependent manner (P < .05), and its influence was significantly less in vivo on the HMT time than on the kaolin ACT (P < .001). Conclusions: The abilities of the HMT and the kaolin ACT to measure anticoagulation effects were not significantly different. Aprotinin prolonged both the kaolin ACT and the HMT time in a dose-dependent manner, but the HMT was significantly less affected by aprotinin in vivo. The HMT is a reliable alternative to measuring the ACT in cardiac operations and may offer greater accuracy in aprotinin-treated patients.
References
[Bayer] Bayer Health Care. 1999. Rapidpoint Coag operator's manual. West Haven, Conn: Bayer Health Care. Cohen EJ, Camerlengo LJ, Dearing JP. 1980. Activated clotting time and CPB, I: the effect of hemodilution and hypothermia upon activated clotting time. J Extra Corpor Technol 12:139-41.nCulliford AT, Gitel SN, Starr N, et al. 1981. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 193:105-11.nDespotis GJ, Filos KS, Levine V, Alsoufiev A, Spitznagel E. 1996. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg 82:1126-31.nDietrich W, Jochum M. 1995. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 109:177-8.nDietrich W, Spannagl M, Jochum M, et al. 1990. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 73:1119-26.nEsposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. 1983. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg 85:174-85.nGravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. 1988. Variability of the activated coagulation time. Anesth Analg 67:469-72.nKovacs MJ, Keeney M, MacKinnon K, Boyle E. 1999. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 21:55-60.nMoorehead MT, Westengard JC, Bull BS. 1984. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 63:394-8.nMurray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. 1997. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 11:24-8.nTeien An, Lie M, Abilgaard U. 1976. Assay of heparin in plasma using achromogenic substrate for activated factor X. Thromb Res 8:413-6.nWang JS, Lin CY, Hung WT, Karp RB. 1992. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 77:1080-4.nWendel HP, Heller W, Gallimore MJ, Bantel H, Muller-Beissenhirtz H, Hoffmeister HE. 1993. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 4:41-5.n
